Přehled o publikaci
2025
Changes in metabolite profiles in the cerebrospinal fluid and in human neuronal cells upon tick-borne encephalitis virus infection
SUYAMA, Satoshi; Sally BOXALL; Benjamin GRACE; Andrea FOŘTOVÁ; Martina PÝCHOVÁ et. al.Basic information
Original name
Changes in metabolite profiles in the cerebrospinal fluid and in human neuronal cells upon tick-borne encephalitis virus infection
Authors
SUYAMA, Satoshi; Sally BOXALL; Benjamin GRACE; Andrea FOŘTOVÁ; Martina PÝCHOVÁ; Lenka KRBKOVÁ; Rupasri MANDAL; David WISHART; Diane E GRIFFIN; Daniel RŮŽEK and Niluka GOONAWARDANE
Edition
Journal of neuroinflammation, London, BioMed Central Ltd, 2025, 1742-2094
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001508094700001
EID Scopus
2-s2.0-105007994515
Keywords in English
Tick-borne encephalitis virus; Cerebrospinal fluid; Human motor neurons; Metabolomics; Pro-inflammatory cytokines; Chemokines; Neuroinflammation
Links
LX22NPO5103, research and development project. NU22-05-00659, research and development project.
Changed: 24/6/2025 00:50, RNDr. Daniel Jakubík
Abstract
V originále
gt;= 3.2) higher in encephalitis patients compared to the meningitis group. CSF urocanic acid levels were significantly lower in patients with encephalitis compared to those with meningitis (p = 0.012209). Follow-up analyses showed fluctuations in the levels of O-phosphoethanolamine, succinic acid, and L-proline in the encephalitis group, and pyruvic acid in the meningitis group. TBEV-infection of hMNs increased the production of SAM, FBP1 and PEP in a time-dependent manner. Depletion of the metabolites with characterised pharmacological inhibitors led to a concentration-dependent attenuation of virus growth, validating the identified changes as key mediators of TBEV infection.ConclusionsOur findings reveal that the neurological disease outcome of TBEV infection is associated with specific and dynamic metabolic signatures in the cerebrospinal fluid. We describe a new in vitro model for in-depth studies of TBEV-induced neuropathogenesis, in which the depletion of identified metabolites limits virus infection. Collectively, this reveals new biomarkers that can differentiate and predict TBEV-associated neurological disease. Additionally, we have identified novel therapeutic targets with the potential to significantly improve patient outcomes and deepen our understanding of TBEV pathogenesis.